gms | German Medical Science

73. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC)
Joint Meeting mit der Griechischen Gesellschaft für Neurochirurgie

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

29.05. - 01.06.2022, Köln

Article

Send article

The clinical and prognostic role of S100B expression in meningiomas

Die klinische und prognostische Rolle der Expression von S100B in Meningeomen

Meeting Abstract

Search Medline for

  • presenting/speaker Felix Behling - Universitätsklinikum Tübingen, Klinik für Neurochirurgie, Tübingen, Deutschland
  • Christina Fodi - Universitätsklinikum Tübingen, Klinik für Neurochirurgie, Tübingen, Deutschland; Universitätsklinikum Tübingen, Klinik für Neurologie, Tübingen, Deutschland
  • Jürgen B. Honegger - Universitätsklinikum Tübingen, Klinik für Neurochirurgie, Tübingen, Deutschland
  • Ghazaleh Tabatabai - Universitätsklinikum Tübingen, Klinik für Neurochirurgie, Tübingen, Deutschland; Universitätsklinikum Tübingen, Klinik für Neurologie, Tübingen, Deutschland
  • Marcos Tatagiba - Universitätsklinikum Tübingen, Klinik für Neurochirurgie, Tübingen, Deutschland
  • Jens Schittenhelm - Universitätsklinikum Tübingen, Institut für Neuropathologie, Tübingen, Deutschland

Deutsche Gesellschaft für Neurochirurgie. 73. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Griechischen Gesellschaft für Neurochirurgie. Köln, 29.05.-01.06.2022. Düsseldorf: German Medical Science GMS Publishing House; 2022. DocP119

doi: 10.3205/22dgnc429, urn:nbn:de:0183-22dgnc4299

Published: May 25, 2022

© 2022 Behling et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. See license information at http://creativecommons.org/licenses/by/4.0/.

Outline

Text

Objective: The prognostic assessment in meningiomas is or high importance to detect patients at risk of recurrence as early as possible. Recently, an integrative molecular classification of meningiomas with prognostic impact has been described. There is first evidence that S100 may be a marker associated with a favorable clinical course.

Methods: We therefore assessed the immunohistochemical expression of S100 in our meningioma cohort of 1664 paraffin-embedded and formalin-fixated tumor tissue samples. A semi-quantitative scoring system was applied. Correlations with clinical parameters were done (gender, age, NF2, prior radiotherapy, histological subtype, WHO grade, proliferation activity and time to tumor recurrence).

Results: A strong expression of S100 was seen in 195 meningiomas (11.7%). A higher rate of cases with high expression was seen with female gender (p= 0.0004), NF2 (p< 0.0001), spinal and convexity/falx location (p< 0.0001) and WHO grade I (p= 0.0073). Kaplan-Meier Analysis showed a favorable disease course for meningiomas showing a strong expression of S100 (p= 0.0099) but multivariate analysis did not confirm a prognostic effect for S100.

Conclusion: Strong immunohistochemical expression of S100 is associated with benign meningiomas but is not an independent prognostic marker.